The Saudi Critical Care Society practice guidelines on the management of COVID-19 in the ICU: Therapy section

Waleed Alhazzani, Mohammed Alshahrani, Fayez Alshamsi, Ohoud Aljuhani, Khalid Eljaaly, Samaher Hashim, Rakan Alqahtani, Doaa Alsaleh, Zainab Al Duhailib, Haifa Algethamy, Tariq Al-Musawi, Thamir Alshammari, Abdullah Alqarni, Danya Khoujah, Wail Tashkandi, Talal Dahhan, Najla Almutairi, Haleema A. Alserehi, Maytha Al-Yahya, Bandar Al-Judaibi Yaseen M. Arabi, Jameel Abualenain, Jawaher M. Alotaibi, Ali Al bshabshe, Reham Alharbi, Fahad Al-Hameed, Alyaa Elhazmi, Reem S. Almaghrabi, Fatma Almaghlouth, Malak Abedalthagafi, Noor Al Khathlan, Faisal A. Al-Suwaidan, Reem F. Bunyan, Bandar Baw, Ghassan Alghamdi, Manal Al Hazmi, Yasser Mandourah, Abdullah Assiri, Mushira Enani, Maha Alawi, Reem Aljindan, Ahmed Aljabbary, Abdullah Alrbiaan, Fahd Algurashi, Abdulmohsen Alsaawi, Thamer H. Alenazi, Mohammed A. Alsultan, Saleh A. Alqahtani , Ziad Memish, Jaffar A. Al-Tawfiq, Ahmed Al-jedai Show 31 others Show less

Research output : Contribution to journal › Article › peer-review

Abstract

Background: The rapid increase in coronavirus disease 2019 (COVID-19) cases during the subsequent waves in Saudi Arabia and other countries prompted the Saudi Critical Care Society (SCCS) to put together a panel of experts to issue evidence-based recommendations for the management of COVID-19 in the intensive care unit (ICU). Methods: The SCCS COVID-19 panel included 51 experts with expertise in critical care, respirology, infectious disease, epidemiology, emergency medicine, clinical pharmacy, nursing, respiratory therapy, methodology, and health policy. All members completed an electronic conflict of interest disclosure form. The panel addressed 9 questions that are related to the therapy of COVID-19 in the ICU. We identified relevant systematic reviews and clinical trials, then used the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach as well as the evidence-to-decision framework (EtD) to assess the quality of evidence and generate recommendations. Results: The SCCS COVID-19 panel issued 12 recommendations on pharmacotherapeutic interventions (immunomodulators, antiviral agents, and anticoagulants) for severe and critical COVID-19, of which 3 were strong recommendations and 9 were weak recommendations. Conclusion: The SCCS COVID-19 panel used the GRADE approach to formulate recommendations on therapy for COVID-19 in the ICU. The EtD framework allows adaptation of these recommendations in different contexts. The SCCS guideline committee will update recommendations as new evidence becomes available.

Keywords

• COVID-19
• Intensive care unit
• Practice guideline
• Therapy

ASJC Scopus subject areas

• Public Health, Environmental and Occupational Health
• Infectious Diseases

Access to Document

Other files and links

Fingerprint

Dive into the research topics of 'The Saudi Critical Care Society practice guidelines on the management of COVID-19 in the ICU: Therapy section'. Together they form a unique fingerprint.

• Practice Guidelines Keyphrases 100%

Cite this

• APA
• Standard
• Harvard
• Vancouver
• Author
• BIBTEX
• RIS

Alhazzani, W., Alshahrani, M., Alshamsi, F., Aljuhani, O., Eljaaly, K., Hashim, S., Alqahtani, R., Alsaleh, D., Al Duhailib, Z., Algethamy, H., Al-Musawi, T., Alshammari, T., Alqarni, A., Khoujah, D., Tashkandi, W., Dahhan, T., Almutairi, N., Alserehi, H. A., Al-Yahya, M., . Al-jedai, A. (2022). The Saudi Critical Care Society practice guidelines on the management of COVID-19 in the ICU: Therapy section . Journal of Infection and Public Health , 15(1), 142-151. https://doi.org/10.1016/j.jiph.2021.10.005

Research output : Contribution to journal › Article › peer-review

Alhazzani, W, Alshahrani, M, Alshamsi, F, Aljuhani, O, Eljaaly, K, Hashim, S, Alqahtani, R, Alsaleh, D, Al Duhailib, Z, Algethamy, H, Al-Musawi, T, Alshammari, T, Alqarni, A, Khoujah, D, Tashkandi, W, Dahhan, T, Almutairi, N, Alserehi, HA, Al-Yahya, M, Al-Judaibi, B, Arabi, YM, Abualenain, J, Alotaibi, JM, Al bshabshe, A, Alharbi, R, Al-Hameed, F, Elhazmi, A, Almaghrabi, RS, Almaghlouth, F, Abedalthagafi, M, Al Khathlan, N, Al-Suwaidan, FA, Bunyan, RF, Baw, B, Alghamdi, G, Al Hazmi, M, Mandourah, Y, Assiri, A, Enani, M, Alawi, M, Aljindan, R, Aljabbary, A, Alrbiaan, A, Algurashi, F, Alsaawi, A, Alenazi, TH, Alsultan, MA , Alqahtani, SA , Memish, Z, Al-Tawfiq, JA & Al-jedai, A 2022, ' The Saudi Critical Care Society practice guidelines on the management of COVID-19 in the ICU: Therapy section ', Journal of Infection and Public Health , vol. 15, no. 1, pp. 142-151. https://doi.org/10.1016/j.jiph.2021.10.005

title = "The Saudi Critical Care Society practice guidelines on the management of COVID-19 in the ICU: Therapy section",

abstract = "Background: The rapid increase in coronavirus disease 2019 (COVID-19) cases during the subsequent waves in Saudi Arabia and other countries prompted the Saudi Critical Care Society (SCCS) to put together a panel of experts to issue evidence-based recommendations for the management of COVID-19 in the intensive care unit (ICU). Methods: The SCCS COVID-19 panel included 51 experts with expertise in critical care, respirology, infectious disease, epidemiology, emergency medicine, clinical pharmacy, nursing, respiratory therapy, methodology, and health policy. All members completed an electronic conflict of interest disclosure form. The panel addressed 9 questions that are related to the therapy of COVID-19 in the ICU. We identified relevant systematic reviews and clinical trials, then used the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach as well as the evidence-to-decision framework (EtD) to assess the quality of evidence and generate recommendations. Results: The SCCS COVID-19 panel issued 12 recommendations on pharmacotherapeutic interventions (immunomodulators, antiviral agents, and anticoagulants) for severe and critical COVID-19, of which 3 were strong recommendations and 9 were weak recommendations. Conclusion: The SCCS COVID-19 panel used the GRADE approach to formulate recommendations on therapy for COVID-19 in the ICU. The EtD framework allows adaptation of these recommendations in different contexts. The SCCS guideline committee will update recommendations as new evidence becomes available.",

author = "Waleed Alhazzani and Mohammed Alshahrani and Fayez Alshamsi and Ohoud Aljuhani and Khalid Eljaaly and Samaher Hashim and Rakan Alqahtani and Doaa Alsaleh and , Zainab and Haifa Algethamy and Tariq Al-Musawi and Thamir Alshammari and Abdullah Alqarni and Danya Khoujah and Wail Tashkandi and Talal Dahhan and Najla Almutairi and Alserehi, and Maytha Al-Yahya and Bandar Al-Judaibi and Arabi, and Jameel Abualenain and Alotaibi, and , Ali and Reham Alharbi and Fahad Al-Hameed and Alyaa Elhazmi and Almaghrabi, and Fatma Almaghlouth and Malak Abedalthagafi and , Noor and Al-Suwaidan, and Bunyan, and Bandar Baw and Ghassan Alghamdi and , Manal and Yasser Mandourah and Abdullah Assiri and Mushira Enani and Maha Alawi and Reem Aljindan and Ahmed Aljabbary and Abdullah Alrbiaan and Fahd Algurashi and Abdulmohsen Alsaawi and Alenazi, and Alsultan, and Alqahtani, and Ziad Memish and Al-Tawfiq, and Ahmed Al-jedai",

T1 - The Saudi Critical Care Society practice guidelines on the management of COVID-19 in the ICU

T2 - Therapy section

AU - Alhazzani, Waleed

AU - Alshahrani, Mohammed

AU - Alshamsi, Fayez

AU - Aljuhani, Ohoud

AU - Eljaaly, Khalid

AU - Hashim, Samaher

AU - Alqahtani, Rakan

AU - Alsaleh, Doaa

AU - Al Duhailib, Zainab

AU - Algethamy, Haifa

AU - Al-Musawi, Tariq

AU - Alshammari, Thamir

AU - Alqarni, Abdullah

AU - Khoujah, Danya

AU - Tashkandi, Wail

AU - Dahhan, Talal

AU - Almutairi, Najla

AU - Alserehi, Haleema A.

AU - Al-Yahya, Maytha

AU - Al-Judaibi, Bandar

AU - Arabi, Yaseen M.

AU - Abualenain, Jameel

AU - Alotaibi, Jawaher M.

AU - Al bshabshe, Ali

AU - Alharbi, Reham

AU - Al-Hameed, Fahad

AU - Elhazmi, Alyaa

AU - Almaghrabi, Reem S.

AU - Almaghlouth, Fatma

AU - Abedalthagafi, Malak

AU - Al Khathlan, Noor

AU - Al-Suwaidan, Faisal A.

AU - Bunyan, Reem F.

AU - Alghamdi, Ghassan

AU - Al Hazmi, Manal

AU - Mandourah, Yasser

AU - Assiri, Abdullah

AU - Enani, Mushira

AU - Aljindan, Reem

AU - Aljabbary, Ahmed

AU - Alrbiaan, Abdullah

AU - Algurashi, Fahd

AU - Alsaawi, Abdulmohsen

AU - Alenazi, Thamer H.

AU - Alsultan, Mohammed A.

AU - Alqahtani, Saleh A.

AU - Memish, Ziad

AU - Al-Tawfiq, Jaffar A.

AU - Al-jedai, Ahmed

N1 - Publisher Copyright: © 2021

N2 - Background: The rapid increase in coronavirus disease 2019 (COVID-19) cases during the subsequent waves in Saudi Arabia and other countries prompted the Saudi Critical Care Society (SCCS) to put together a panel of experts to issue evidence-based recommendations for the management of COVID-19 in the intensive care unit (ICU). Methods: The SCCS COVID-19 panel included 51 experts with expertise in critical care, respirology, infectious disease, epidemiology, emergency medicine, clinical pharmacy, nursing, respiratory therapy, methodology, and health policy. All members completed an electronic conflict of interest disclosure form. The panel addressed 9 questions that are related to the therapy of COVID-19 in the ICU. We identified relevant systematic reviews and clinical trials, then used the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach as well as the evidence-to-decision framework (EtD) to assess the quality of evidence and generate recommendations. Results: The SCCS COVID-19 panel issued 12 recommendations on pharmacotherapeutic interventions (immunomodulators, antiviral agents, and anticoagulants) for severe and critical COVID-19, of which 3 were strong recommendations and 9 were weak recommendations. Conclusion: The SCCS COVID-19 panel used the GRADE approach to formulate recommendations on therapy for COVID-19 in the ICU. The EtD framework allows adaptation of these recommendations in different contexts. The SCCS guideline committee will update recommendations as new evidence becomes available.

AB - Background: The rapid increase in coronavirus disease 2019 (COVID-19) cases during the subsequent waves in Saudi Arabia and other countries prompted the Saudi Critical Care Society (SCCS) to put together a panel of experts to issue evidence-based recommendations for the management of COVID-19 in the intensive care unit (ICU). Methods: The SCCS COVID-19 panel included 51 experts with expertise in critical care, respirology, infectious disease, epidemiology, emergency medicine, clinical pharmacy, nursing, respiratory therapy, methodology, and health policy. All members completed an electronic conflict of interest disclosure form. The panel addressed 9 questions that are related to the therapy of COVID-19 in the ICU. We identified relevant systematic reviews and clinical trials, then used the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach as well as the evidence-to-decision framework (EtD) to assess the quality of evidence and generate recommendations. Results: The SCCS COVID-19 panel issued 12 recommendations on pharmacotherapeutic interventions (immunomodulators, antiviral agents, and anticoagulants) for severe and critical COVID-19, of which 3 were strong recommendations and 9 were weak recommendations. Conclusion: The SCCS COVID-19 panel used the GRADE approach to formulate recommendations on therapy for COVID-19 in the ICU. The EtD framework allows adaptation of these recommendations in different contexts. The SCCS guideline committee will update recommendations as new evidence becomes available.

KW - Intensive care unit

KW - Practice guideline